Orlistat Reformulation Saves Organs in Critical Care
Proprietary Orlistat Formulation for Organ Failure
Tags: Monash University, Australia, Healthcare & Lifesciences
A novel orlistat formulation targets organ failure in acute critical conditions like sepsis and trauma through oral or enteric administration. It works by systemically delivering orlistat, traditionally an anti-obesity drug, to inhibit enzymes contributing to organ failure. This formulation can reach the systemic circulation via lymphatics, offering a potential protective measure against organ failure across various critical illnesses. It represents a significant advancement in emergency and critical care medicine, with the potential to significantly reduce mortality in patients with no standard care treatment.
IP Type or Form Factor: Patent Pending; Platform
TRL: 5 - prototype ready for testing in intended environment
Industry or Tech Area: Pharmaceutical Engineering; Healthcare Provider
